DiscoverThe Lancet Gastroenterology & Hepatology in conversation withJulia Mayerle on the validation of plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma
Julia Mayerle on the validation of plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma

Julia Mayerle on the validation of plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma

Update: 2025-06-19
Share

Description

Can a multi-metabolite blood test improve early pancreatic cancer detection? We spoke to Julia Mayerle about the METAPAC study, which sought to validate the ability of plasma metabolic signatures to find resectable tumors and reduce unnecessary invasive procedures in high-risk patients.

Read the full article:

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00056-1/fulltext?dgcid=buzzsprout_icw_podcast_June_25_langas

Continue this conversation on social!

Follow us today at...

https://bsky.app/profile/lancetgastrohep.bsky.social

https://www.linkedin.com/company/langastro/

https://instagram.com/thelancetgroup

https://facebook.com/thelancetmedicaljournal

https://youtube.com/thelancettv

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Julia Mayerle on the validation of plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma

Julia Mayerle on the validation of plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma

The Lancet Group